NCT01196676View on ClinicalTrials.gov

Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4451

PHASE1CompletedINTERVENTIONAL

Enrollment

63

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

April 30, 2011

Study Completion Date

April 30, 2011

Conditions

Bipolar Disorder

Interventions

DRUG

AZD4451

1 mg capsules, 5 mg capsules, and 25 mg capsules

DRUG

Placebo

1 mg capsules, 5 mg capsules, and 25 mg capsules

Trial Locations (1)

Unknown

Research Site, Overland Park

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AstraZeneca

INDUSTRY